(Reuters) -Consumer healthcare firm Haleon (LON:HLN) said on Wednesday that Dawn Allen has been appointed as its new chief financial officer, effective Nov. 1.
Allen, 55, currently CFO at British food ingredients maker Tate & Lyle (LON:TATE), replaces Tobias Hestler.
The change in CFO has taken place less than two months after Haleon unveiled its plan to buy back 500 million pounds ($622.2 million) of its shares this year, partly in its bid to reduce debt.
Hestler, 52, was CFO of GSK (LON:GSK)'s consumer wing from 2018 and held the top finance role since the formation of Haleon.
Haleon, which makes household brands such as Sensodyne toothpaste and Advil painkillers, was spun out of British drugmaker GSK in July 2022. It was formed in 2019 by merging GSK and Pfizer (NYSE:PFE)'s consumer healthcare businesses.
Both GSK and Pfizer have sold down their stake in Haleon since then, with the latter remaining as the London-listed firm's largest shareholder.
($1 = 0.8037 pounds)